Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282282 · ClinicalTrials.gov registry record · Phase 2
Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00282282 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 31 participants.
The verdict
NCT00282282, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to extend the use of Tacrolimus and Sirolimus to determine how effective it is in preventing graft versus host disease (GVHD)in patients that have received non-myeloablative peripheral blood stem cell transplantation.
Interventions
- DRUG fludarabine
- DRUG tacrolimus
- DRUG sirolimus
- DRUG busulfex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2006-01 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00282282
The ClinicalTrials.gov registry entry for NCT00282282 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which fludarabine is the first listed.
NCT00282282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00282282 about?
NCT00282282 is a clinical study titled "Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation". The purpose of this study is to extend the use of Tacrolimus and Sirolimus to determine how effective it is in preventing graft versus host disease (GVHD)in patients that have received non-myeloablative peripheral blood stem cell transplantation.
What is the current status of trial NCT00282282?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2006-01. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00282282?
The interventions under investigation include: fludarabine (DRUG), tacrolimus (DRUG), sirolimus (DRUG), busulfex (DRUG).
Who is sponsoring clinical trial NCT00282282?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.